| Autor: |
Joseph Y Abrams, Ermias D Belay, Shana Godfred-Cato, Angela P Campbell, Laura D Zambrano, Amber Kunkel, Allison D Miller, Michael J Wu, Lu Meng, Ami B Shah, Matthew E Oster |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(7) |
| ISSN: |
1537-6591 |
| Popis: |
Background Multisystem inflammatory syndrome in children (MIS-C) is a novel severe postinfectious condition associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The purpose of this report is to describe nationwide trends in the evolving clinical management of MIS-C. Methods Patients with MIS-C were reported from state and local jurisdictions to the Centers for Disease Control and Prevention’s (CDC’s) MIS-C national surveillance system. Patients’ case reports were reviewed to ensure that they met the CDC MIS-C case definition and had sufficient data for analysis. The prevalence of use of treatments for MIS-C, temporal trends in use of these treatments, and frequency of administration of different treatment combinations were analyzed. Results There were 4470 patients meeting the MIS-C case definition with onset dates from 19 February 2020 to 31 July 2021. The proportion of patients admitted to an intensive care unit (ICU) has declined over time, from 78.7% in April 2020 to 57.5% in June 2021 (P = .001). The most common treatments were intravenous immunoglobulin (IVIG), given to 85.6% of patients; steroids (77.7%), and antiplatelet medications (73.7%); use of each of these treatments has increased over time, particularly in patients not requiring admission to an ICU (all P Conclusions IVIG, steroids, and antiplatelet medication have become increasingly utilized as standard treatment for MIS-C patients, while the use of other treatments may be contingent on the type and severity of clinical findings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
